Celastrol attenuates osteoclast-driven bone invasion in pituitary adenomas and suppresses HSP90AA1/TRAF6/NF-κB signaling.
Bone-invasive pituitary adenomas (BIPAs) are associated with skull base destruction, incomplete resection and postoperative recurrence, but pharmacological strategies targeting tumor-induced osteolysis remain limited. Here, we investigated whether celastrol, a bioactive triterpenoid from Tripterygium wilfordii, restrai...